SCHEMBL26609261

SCHEMBL26609261

CN1CCN(c2cc[c]cc2Br)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADRA2C P18825 2/20 0.41
▸ DRD2 P14416 4/20 0.39
▸ DRD3 P35462 4/20 0.39
▸ MAPT P10636 4/20 0.38
▸ KDM4E B2RXH2 3/20 0.38
▸ GAA P10253 2/20 0.38
▸ PTK2B Q14289 2/20 0.38
▸ MAPK1 P28482 2/20 0.38
▸ HTT P42858 1/20 0.38
▸ RECQL P46063 1/20 0.38
▸ POLB P06746 2/20 0.37
▸ ALDH1A1 P00352 2/20 0.37
▸ RAD52 P43351 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ KMT2A Q03164 3/20 0.35
▸ LMNA P02545 2/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ HTR6 P50406 1/20 0.35
▸ GFER P55789 1/20 0.35
▸ ESR2 Q92731 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL188362 0.80 ADRA2C (0.42) ADRA2CDRD2DRD3MAPTKDM4E
SCHEMBL4113163 0.80 DRD2 (0.51) ADRA2CDRD2DRD3MAPTKDM4E
SCHEMBL26610433 0.79 MAPT (0.45) MAPTKDM4EGAAMAPK1HTT
SCHEMBL188725 0.79 ALDH1A1 (0.44) ADRA2CDRD2DRD3MAPTKDM4E
SCHEMBL29036649 0.79 ADRA2C (0.58) ADRA2CDRD2DRD3MAPTKDM4E
SCHEMBL16463118 0.78 ADRA2C (0.43) ADRA2CDRD2DRD3MAPTKDM4E
SCHEMBL3584991 0.77 ALDH1A1 (0.41) ADRA2CDRD2DRD3MAPTKDM4E
SCHEMBL16462498 0.77 ROCK2 (0.46) ADRA2CDRD2DRD3MAPTKDM4E
SCHEMBL188354 0.76 DRD2 (0.60) ADRA2CDRD2DRD3MAPTKDM4E
SCHEMBL4117842 0.76 ADRA2C (0.39) ADRA2CDRD2DRD3MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230339904-A1 ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS BIOTHERYX, INC. 2023-10-26 — — US claimed
US-20230339904-A1 ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS BIOTHERYX, INC. 2023-10-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230339904-A1 ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS CSNK1A1, CSNK1D, CSNK1G1 ADRA2C 1194/4885DRD2 2393/4885DRD3 2693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback